More About Vineeta
Vineeta Agarwala, MD, PhD is a General Partner at a16z, where she leads investments for the firm’s Bio + Health fund across biotech, life sciences software, and digital health, with a focus on companies leveraging unique technologies and datasets to improve drug development and patient care delivery.
Prior to joining a16z, Vineeta held many different roles in the healthcare space: as a physician taking care of patients; as an operator at healthtech startups; and as a venture investor on the GV (Google Ventures) life sciences team. She was an early data scientist at Kyruus; a management consultant for biotech, pharmaceutical, and medical device clients at McKinsey & Co; and a Director of Product Management at Flatiron Health, where she led the company’s partnership with Foundation Medicine to integrate real-world clinical and genomic data into national-scale data products to accelerate research and development in oncology. She has conducted academic research at Cold Spring Harbor Laboratory, Lawrence Livermore National Laboratory, and the Broad Institute, where she did graduate work in computational biology and human genetics.
Vineeta holds a B.S. in biophysics from Stanford University, and MD and PhD degrees from Harvard Medical School/MIT. She completed her clinical residency at Stanford, and is board certified in internal medicine. Vineeta continues to see patients at Stanford as an adjunct clinical professor in the Division of Primary Care and Population Health.
Vineeta serves on a number of portfolio company boards, including Amber Bio, BigHat Biosciences, Function Oncology, GC Therapeutics, Orbital Therapeutics, Rezo Therapeutics, Memora Health, Pearl Health, Pomelo Care, Thyme Care, and Waymark.
As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.
As we have seen the Pomelo team build out their virtual clinic, care model, and software platform, they are dedicated to a few key principles which we believe are absolutely critical to building a scalable company in this space.
Orbital is taking advantage of what is already known, but also innovating with urgency to make RNA-based therapeutics impactful and accessible for a much wider set of patients worldwide.
“The power in tailored therapeutics is for us to say more clearly to payers, providers, and patients: ‘this drug is not for everyone, but it is for you.’ That is exceedingly powerful.” —John C. Lechleiter, Ph....
We’re rebooting our Journal Club series! Going forward, these episodes will be interspersed in our regular feed. In this episode, Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Instit...
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.